Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.
about
Arterial thrombosis in four patients treated with thalidomideEarly postmarketing drug safety surveillance: data mining points to consider.Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.Thalidomide: dual benefits in palliative medicine and oncology.The use of novel agents in multiple myeloma patients with hepatic impairment.Dermatologic and nondermatologic uses of thalidomide.A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report.Lenalidomide in multiple myeloma.Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.Palliative oncology: thalidomide.Antineoplastic drug-induced bradyarrhythmias.Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database.Cancer chemotherapy and cardiac arrhythmias: a review.Life-threatening dermatologic adverse events in oncologyThalidomide-induced sinus bradycardia.Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus.An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report.Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature.Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.
P2860
Q28212339-61D5AAEC-F433-441B-A0CF-CBB966BDD719Q30951778-66F01FAB-745E-4918-9B32-A4E86B3FD7FEQ33654733-8C3118D9-2A00-4CA2-B25E-A57D8E502D9CQ34375023-AC315E81-ECA7-494E-905A-6C2C33671A32Q35182819-7977F687-8E94-450A-9A14-F0A85370F24AQ35201057-F455CBEC-8ABC-44F6-9105-354D97D16AA2Q36406118-120FA73A-8F64-4118-866C-E76C67085823Q36573818-97BBF23A-38CA-4BA1-A9B5-AF10590E691BQ37038711-04CB45A2-BD57-4AFB-AD51-7AD71E2CCAEDQ37618475-275FD90D-7B1C-4F7D-B3F5-EB2244708F98Q38025714-09AA6EBA-9EE5-43E6-9F4C-FFED68FF8677Q38146900-8852E875-EAD7-4490-9FF8-5D71C76F5B41Q38313870-46534DCB-3A96-4E10-9A54-B7F18FDCBBC4Q41869634-FF541C2F-3D48-4853-A197-F96405264BBAQ42166156-4DBF202B-B941-4749-ADC3-ECDC84B2BB37Q43962381-31D16833-A2E9-46A6-93D9-5005451711EEQ44006206-174F5B96-D77E-4F6B-A88E-A3A6A43C5260Q44163487-52FB77AE-94B0-4AA3-A186-C675F22F2B29Q48115785-F2B2FFE4-2A9D-480C-A422-F872423ABDCDQ54987295-CB512EC4-512F-4371-AD05-318238D12054
P2860
Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Thalomid (Thalidomide) capsule ...... cluding off-label prescribing.
@ast
Thalomid (Thalidomide) capsule ...... cluding off-label prescribing.
@en
type
label
Thalomid (Thalidomide) capsule ...... cluding off-label prescribing.
@ast
Thalomid (Thalidomide) capsule ...... cluding off-label prescribing.
@en
prefLabel
Thalomid (Thalidomide) capsule ...... cluding off-label prescribing.
@ast
Thalomid (Thalidomide) capsule ...... cluding off-label prescribing.
@en
P2093
P1433
P1476
Thalomid (Thalidomide) capsule ...... cluding off-label prescribing.
@en
P2093
P304
P356
10.2165/00002018-200124020-00002
P577
2001-01-01T00:00:00Z
P6179
1001956903